Sepsis Research Analysis
June’s sepsis research converged on targetable host-response biology while delivering practice-changing randomized evidence. Mechanistic papers prioritized endoplasmic reticulum stress nodes (IκBζ–XBP1s/Regnase‑1 and DAPK2–HSPA5–IRE1α) as drivers of hyperinflammation, rising to the top after score normalization with recency weighting. Large adaptive and multicenter RCTs supported safer definitive beta‑lactam choices for MSSA/PSSA bacteremia and individualized shorter antibiotic courses in cultur
Summary
June’s sepsis research converged on targetable host-response biology while delivering practice-changing randomized evidence. Mechanistic papers prioritized endoplasmic reticulum stress nodes (IκBζ–XBP1s/Regnase‑1 and DAPK2–HSPA5–IRE1α) as drivers of hyperinflammation, rising to the top after score normalization with recency weighting. Large adaptive and multicenter RCTs supported safer definitive beta‑lactam choices for MSSA/PSSA bacteremia and individualized shorter antibiotic courses in culture‑negative neonatal EOS. Complementary advances included neuroendocrine and neuroinflammatory mechanisms, precision immune endotyping, and pragmatic diagnostic/process innovations (presepsin, blood-targeted microbial cfDNA sequencing, and LLM-enabled quality improvement).
Selected Articles
1. ER stress amplifies inflammation via a dual mechanism involving IκBζ-XBP1s synergism and Regnase-1 degradation.
This mechanistic study demonstrates that ER stress amplifies IL-6 and selective secondary-response genes through (1) IKK-dependent Regnase-1 degradation stabilizing Nfkbiz mRNA and (2) transcriptional synergy between IκBζ and XBP1s; both layers are required for excessive IL-6 in septic mice, nominating actionable molecular nodes.
Impact: Defines a dual transcriptional/post-transcriptional ER stress mechanism driving hyperinflammation with in vivo validation, revealing druggable targets (IκBζ, XBP1s, Regnase-1).
Clinical Implications: Therapeutically targeting IκBζ accumulation, preserving Regnase-1, or disrupting IκBζ–XBP1s cooperativity could attenuate IL‑6–driven immunopathology in sepsis; requires selective modulators and biomarker-led selection.
Key Findings
- ER stress synergizes with TLR signaling to upregulate IκBζ in macrophages.
- Ca2+-dependent IKK activity degrades Regnase-1, stabilizing Nfkbiz mRNA and promoting IκBζ accumulation.
- IκBζ cooperates with XBP1s to drive selective secondary-response genes (e.g., Il6, Nos2) and is required for excessive IL-6 in septic mice.
2. Cefazolin for Methicillin-Susceptible
In an international Bayesian adaptive, open‑label randomized comparison, cefazolin was noninferior to antistaphylococcal penicillins for 90‑day mortality and significantly reduced acute kidney injury, supporting cefazolin as a safer definitive beta‑lactam for MSSA-like infections.
Impact: Resolves a long-standing question on definitive MSSA therapy with randomized evidence, demonstrating kidney safety without compromising survival.
Clinical Implications: Prefer cefazolin over antistaphylococcal penicillins for confirmed MSSA to minimize nephrotoxicity while maintaining outcomes; optimize workflows for rapid susceptibility reporting to enable timely de‑escalation.
Key Findings
- 90‑day mortality noninferiority: adjusted OR 0.81 (95% CrI 0.59–1.12); noninferiority probability 99.2%.
- Acute kidney injury reduced with cefazolin: adjusted OR 0.67 (95% CrI 0.50–0.89).
- Bayesian adaptive platform provided robust probabilities favoring mortality noninferiority and kidney safety superiority.
3. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
In confirmed PSSA bacteremia, benzylpenicillin showed a high probability of noninferiority for 90‑day mortality versus flucloxacillin/cloxacillin and substantially reduced acute kidney injury, with early termination due to AKI imbalance in the comparator arm.
Impact: Pragmatic international RCT evidence supports benzylpenicillin as a safer definitive agent for PSSA, reducing nephrotoxicity without sacrificing survival.
Clinical Implications: Adopt benzylpenicillin for confirmed PSSA where feasible and expedite susceptibility workflows to enable timely de‑escalation from broader agents.
Key Findings
- High posterior probability of noninferiority for 90‑day mortality (adjusted OR 0.67; 95% CrI 0.35–1.28).
- Acute kidney injury reduced by half in benzylpenicillin arm (adjusted OR 0.50).
- Trial stopped early due to excess AKI in antistaphylococcal penicillin arm.
4. Death-associated protein kinase 2 (DAPK2) propagates endoplasmic reticulum stress in macrophages to worsen sepsis through HSPA5-IRE1α axis.
This preclinical translational study identifies macrophage DAPK2 as a TLR4–MyD88–NF‑κB–induced kinase that phosphorylates HSPA5 (Ser588), promotes its proteasomal degradation, and activates IRE1α; macrophage‑specific DAPK2 deletion reduced ER stress and sepsis severity.
Impact: Links innate immune activation to macrophage ER stress and organ injury via a kinase–chaperone mechanism, nominating a druggable node validated by genetic perturbation and proteomics.
Clinical Implications: Pharmacologic DAPK2 inhibition or stabilizing HSPA5/attenuating IRE1α signaling could mitigate macrophage ER stress; DAPK2 expression may serve as a biomarker for targeted trials.
Key Findings
- DAPK2 is transcriptionally upregulated in sepsis macrophages via TLR4–MyD88–NF‑κB.
- DAPK2 phosphorylates HSPA5 at Ser588, promoting proteasomal degradation and activating IRE1α.
- Macrophage-specific DAPK2 deletion attenuates ER stress and sepsis severity, supporting causality.
5. Individualised duration of antibiotic treatment in culture-negative early-onset sepsis in late-preterm and term-born neonates in Denmark (DURATION): a multicentre, open-label, randomised, controlled, non-inferiority trial.
A nationwide multicentre RCT showed that a clinically guided discontinuation rule (stop at 24 h if no signs and CRP declining to ≤30 mg/L) was noninferior for infection‑related readmission and reduced antibiotic exposure to ~3 days versus standard 5–7 days in culture‑negative EOS.
Impact: Provides robust neonatal evidence enabling stewardship—shorter, individualized antibiotic courses without increased short-term harm in probable EOS.
Clinical Implications: Implement individualized stop rules using serial clinical assessment and CRP kinetics to safely reduce antibiotic exposure in culture‑negative EOS, with structured follow‑up.
Key Findings
- Randomized 493 neonates nationwide (246 individualized vs 247 standard).
- Noninferior infection-related readmission with individualized strategy; no short-term harm signal.
- Median antibiotic duration reduced to ~3 days vs 5–7 days standard.